new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp A Corporation A Subsidiary Of Merck x26 Co Inc
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors




Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15 Mono- and di-peg il-10 production; and uses
22015001159001/08/15 Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12 Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12 Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52016017685806/23/16  new patent  Oxazole orexin receptor antagonists
62016017688406/23/16  new patent  Process for making beta 3 agonists and intermediates
72016017689706/23/16  new patent  7-aminocephem derivative compounds
82016017690506/23/16  new patent  Forms of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
92016016652906/16/16 Formulations for cathepsin k inhibitors with vitamin d
102016016654406/16/16 Oral pharmaceutical formulation of omarigliptin
112016016657606/16/16 Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
122016016664706/16/16 Pegylated interleukin-10
132016015821706/09/16 Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
142016015974406/09/16 Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
152016015821706/09/16 Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
162016015974406/09/16 Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
172016015975206/09/16 Piperazine derivatives as hiv protease inhibitors
182016015977906/09/16 Co-crystal of the par-1 receptor antagonists vorapaxar and asprin
192016015147706/02/16 Dengue virus vaccine compositions and methods of use thereof
202016014389505/26/16 Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
212016014525505/26/16 Non-nucleoside reverse transcriptase inhibitors
222016014527205/26/16 Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
232016013617205/19/16 Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
242016013762205/19/16 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
252016013025905/12/16 Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
262016013027305/12/16 Process for making cgrp receptor antagonists
272016013032705/12/16 Cmv neutralizing antigen binding proteins
282016013057405/12/16 Methods of measuring gene expression in facs-sorted cells
292016013065905/12/16 Compositions and methods for treating cancer
302016012235005/05/16 Process for the preparation of chiral tert-butyl 4-((1r,2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate derivatives and (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
312016012238005/05/16 Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
322016011391004/28/16 Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
332016011400004/28/16 Co-agonists of the glucagon and glp-1 receptors
342016010683504/21/16 Combination therapies for cancer
352016010804804/21/16 Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
362016010805904/21/16 Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
372016010207304/14/16 2-hydroxymethyl-substituted orexin receptor antagonists
382016009685804/07/16 Selective glycosidase inhibitors and uses thereof
392016008200503/24/16 Process of making and using pharmaceutical formulations of antineoplastic agents
402016008376503/24/16 Method for preparing antibodies having improved properties
412016008483903/24/16 Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
422016008484803/24/16 Assay for determining endogenous levels of analyte in vivo
432016007450203/17/16 Recombinant subunit dengue virus vaccine
442016007564503/17/16 Amidation process
452016007565003/17/16 Crystalline polymorphic forms of an antidiabetic compound
462016007565603/17/16 Quinoline amide m1 receptor positive allosteric modulators
472016007568403/17/16 Alpha 7 nicotinic acetylcholine receptor modulators and uses thereof-iii
482016007572403/17/16 Cetp inhibitors
492016006851003/10/16 Hydroxy-substituted orexin receptor antagonists
502016006851403/10/16 Halo and trifluoromethyl substituted orexin receptor antagonists
512016006853203/10/16 Novel compounds that are erk inhibitors
522016006859703/10/16 Fdf03 antibodies and uses thereof
532016006025503/03/16 Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
542016006025603/03/16 Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
552016006027203/03/16 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
562016005325102/25/16 Immobilized ketoreductases and process for making and using immobilized ketoreductase
572016004552602/18/16 2'-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
582016004658102/18/16 Factor xia inhibitors
592016003981702/11/16 Triazolopyridyl compounds as aldosterone synthase inhibitors
602016004012402/11/16 Adapted lepidopteran insect cells for the production of recombinant proteins
612016004020102/11/16 Biocatalytic transamination process
622016004025202/11/16 Methods and compositions for treating cancer
632016004377402/11/16 C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
642016003188202/04/16 Imidazopyridyl compounds as aldosterone synthase inhibitors
652016002409101/28/16 Inhibitors of the renal outer medullary potassium channel
662016002410001/28/16 Process for preparing chiral dipeptidyl peptidase-iv inhibitors
672016001692101/21/16 S-imino-s-oxo-iminothiazine compounds as bace inhibitors, compositions, and their use
682016001692301/21/16 S-imino-s-oxo-iminothiadiazine compounds as bace inhibitors, compositions, and their use
692016001693501/21/16 2-pyridyloxy-4-ether orexin receptor antagonists
702016001694701/21/16 Substituted pyridizinone derivatives as pde10 inhibitors
712016001697501/21/16 C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
722016001703601/21/16 Cell line 3m
732016000836101/14/16 Compositions and methods for treating cancer
742016000968101/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
752016000968201/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
762016000968901/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
772016000969601/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
782016000072101/07/16 Gastro-retentive formulations
792016000092101/07/16 Ceftolozane antibiotic compositions
802016000222401/07/16 Novel indole derivatives useful as anti-diabetic agents
812016000225501/07/16 Antidiabetic bicyclic compounds
822016000225901/07/16 Inhibitors of the renal outer medullary potassium channel
832015037479512/31/15 O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
842015037624912/31/15 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
852015036824612/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
862015036824712/24/15 2,6,7 substituted purines as hdm2 inhibitors
872015036826512/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
882015036826912/24/15 Factor ixa inhibitors
892015036834412/24/15 Mdl-1 ligand
902015036868212/24/15 Immobilized transaminases and process for making and using immobilized transaminase
912015035979312/17/15 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
922015036109812/17/15 Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
932015036110112/17/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
942015035349812/10/15 Substituted isoquinolines as crth2 receptor modulators
952015035351612/10/15 Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as bace inhibitors, compositions, and their use
962015035353512/10/15 Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
972015035355212/10/15 Purine inhibitors of human phosphatidylinositol 3-kinase delta
982015035355312/10/15 2,6,7,8 substituted purines as hdm2 inhibitors
992015035356512/10/15 Btk inhibitors
1002015035357012/10/15 Btk inhibitors
1012015035518412/10/15 Antibodies that bind to human programmed death ligand 1 (pd-l1)
1022015034293112/03/15 Spirocyclic cetp inhibitors
1032015034315312/03/15 Dual chamber mixing syringes and methods of using same
1042015034315712/03/15 Medication injector with near-empty alert
1052015034448712/03/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1062015034450012/03/15 C2,c6 oxacyclic-fused thiazine dioxide compounds as bace inhibitors, compositions, and their use
1072015033564811/26/15 Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases
1082015033694611/26/15 Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
1092015033694811/26/15 Isotopically labeled biaryl urea compounds
1102015033699111/26/15 Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
1112015033701311/26/15 Novel antibacterial agents for the treatment of gram positive infections
1122015033727411/26/15 Pmt2-, och1-, pmt5- mutant cells
1132015032952111/19/15 Process for making reverse transcriptase inhibitors
1142015032953111/19/15 Amino-pyrimidine-containing spleen tyrosine kinase (syk) inhibitors
1152015032953911/19/15 4-pyridinonetriazine derivatives as hiv integrase inhibitors
1162015032954811/19/15 Substituted pyrrolopyrimidines as hdm2 inhibitors
1172015032955711/19/15 Inhibitors of the renal outer medullary potassium channel
1182015032956211/19/15 Factor ixa inhibitors
1192015032961211/19/15 Process for purifying insulin and analogues thereof
1202015032962811/19/15 Liquid formulations for an anti-tnf alpha antibody
1212015032963211/19/15 Solution formulations of engineered anti-il-23p19 antibodies
1222015032072411/12/15 Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
1232015032073311/12/15 Indazole compounds as aldosterone synthase inhibitors
1242015032086011/12/15 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
1252015032203911/12/15 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
1262015032204011/12/15 3-ester-4 substituted orexin receptor antagonists
1272015032204111/12/15 2-pyridyloxy-4-nitrile-4-substituted orexin receptor antagonists
1282015032205611/12/15 Factor ixa inhibitors
1292015032207411/12/15 4-fluoropiperidine orexin receptor antagonists
1302015032251911/12/15 Biomarkers for psoriasis treatment response
1312015031522111/05/15 Nucleoside kinase bypass compositions and methods
1322015031392611/05/15 Syn3 compositions and methods
1332015031514111/05/15 Thrombin inhibitors
1342015031522111/05/15 Nucleoside kinase bypass compositions and methods
1352015031522611/05/15 Disulfide masked prodrug compositions and methods
1362015030609110/29/15 Aldosterone synthase inhibitors
1372015030746410/29/15 Therapeutic thiazolidinone compounds
1382015030746510/29/15 Iminothiadiazine dioxide compounds as bace inhibitors, compositions and their use
1392015030747910/29/15 Cyclobutyl benzimidazoles as pde 10 inhibitors
1402015030748810/29/15 Cyclopropyl imidazopyridine pde10 inhibitors
1412015030748910/29/15 Pyrimidine pde10 inhibitors
1422015030753310/29/15 Spirocyclic sulfones as gamma secretase inhibitors
1432015030758010/29/15 Oxyntomodulin analogs
1442015030759110/29/15 On-column refolding and purifying of lipoproteins
1452015030760610/29/15 Lyophilized spherical pellets of anti-il-23 antibodies
1462015030785010/29/15 Conditional replicating viral vectors
1472015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
1482015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
1492015029756610/22/15 Rorgammat inhibitors
1502015029912210/22/15 Glycosidase inhibitors and uses thereof
1512015029912510/22/15 Prodrug bipyridylaminopyridines as syk inhibitors
1522015029916710/22/15 Regioselective n-2 arylation of indazoles
1532015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
1542015029922410/22/15 Inhibitors of irak4 activity
1552015029922710/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
1562015029924310/22/15 2'-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1572015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
1582015029969010/22/15 Engineered lower eukaryotic host strains deficient in grr1 activity for recombinant protein
1592015029013510/15/15 Process for making agglomerates using acoustic mixing technology
1602015029032510/15/15 Liquid formulations for tnfr:fc fusion proteins
1612015029155810/15/15 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
1622015029156110/15/15 Substituted pyridone derivatives as pde10 inhibitors
1632015029162010/15/15 Glycosidase inhibitors and uses thereof
1642015029168310/15/15 Modified apol1 polypeptides
1652015028436810/08/15 Secondary alcohol substituted triazoles as pde10 inhibitors
1662015028437610/08/15 Mineralocorticoid receptor antagonists
1672015028437910/08/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1682015028438110/08/15 Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
1692015028438910/08/15 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
1702015028441110/08/15 Novel azabenzimidazole hexahydrofuro[e,2-b]furan derivatives
1712015028475310/08/15 Process for the preparation of an intermediate for an orexin receptor antagonists
1722015027465610/01/15 Glycosidase inhibitors and uses thereof
1732015027466410/01/15 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
1742015027467210/01/15 Substituted spiropiperidinyl compounds useful as gpr120 agonists
1752015027470810/01/15 Inhibitors of irak4 activity
1762015027471610/01/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1772015027473910/01/15 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1782015027475510/01/15 Compound diversification using late stage functionalization
1792015027476710/01/15 4'-substituted nucleoside reverse transcriptase inhibitors
1802015027522210/01/15 Crz1 mutant fungal cells
1812015026571509/24/15 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1822015026689509/24/15 Novel compounds that are erk inhibitors
1832015026689709/24/15 Hcv ns3 protease inhibitors
1842015025807409/17/15 Novel compounds that are erk inhibitors
1852015026073109/17/15 Antibodies, kit and detecting amyloid beta oligomers
1862015025075909/10/15 Composition for inhibition of cathepsin k
1872015025203309/10/15 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists
1882015025203409/10/15 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
1892015025334109/10/15 Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
1902015024690209/03/15 Substitued benzofuran compounds and methods of use thereof for the treatment of viral diseases
1912015024691709/03/15 Inhibitors of hepatitis c virus replication
1922015023986608/27/15 Triazolyl derivatives as syk inhibitors
1932015023242808/20/15 Substituted phenyl-spleen tyrosine kinase (syk) inhibitors
1942015023244708/20/15 Crystalline form of a reverse transcriptase inhibitor
1952015022536508/13/15 Indoline compounds as aldosterone synthase inhibitors
1962015022540208/13/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
1972015021809608/06/15 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
1982015021809708/06/15 Glycosidase inhibitors and uses thereof
1992015021814708/06/15 Glycosidase inhibitors and uses thereof
2002015021814908/06/15 Novel benzimidazole tetrahydrofuran derivatives
2012015021816408/06/15 Substituted naphthyridinedione derivatives as hiv integrase inhibitors
2022015021816908/06/15 3-aminocycloalkyl compounds as rorgammat inhibitors and uses thereof
2032015020942407/30/15 Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
2042015021068507/30/15 Novel azabenzimidazole tetrahydropyran derivatives
2052015021068707/30/15 N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
2062015020348707/23/15 Novel azabenzimidazole tetrahydrofuran derivatives
2072015020349607/23/15 Aliphatic spirolactam cgrp receptor antagonists
2082015020351207/23/15 Macrocyclic compounds as hiv integrase inhibitors
2092015019749007/16/15 Crystalline polymorphic forms of an antidiabetic compound
2102015019753107/16/15 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
2112015019757007/16/15 Anti-ilt5 antibodies and ilt5-binding antibody fragments
2122015019777207/16/15 Mammalian expression vector puhab
2132015019040207/09/15 Solid dosage formulations of an orexin receptor antagonists
2142015019143407/09/15 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
2152015019146107/09/15 Pyrazolyl derivatives as syk inhibitors
2162015019149507/09/15 Antidiabetic tricyclic compounds
2172015018250307/02/15 Mineralocorticoid receptor antagonists
2182015017553406/25/15 Alpha-7 nicotinic acetylcholine receptor modulators and uses therof-i
2192015017557506/25/15 Imidazolyl analogs as syk inhibitors
2202015017560906/25/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
2212015016648606/18/15 Substituted diazine and triazine spleen tyrosine kinease (syk) inhibitors
2222015016649006/18/15 Mineralocorticoid receptor antagonists
2232015016652006/18/15 Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
2242015015893506/11/15 Protective vaccine based on staphylococcus aureus sa2493 protein
2252015015099006/04/15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
2262015015212706/04/15 Permeable glycosidase inhibitors and uses thereof
2272015014733705/28/15 Crystalline anti-human il-23 antibodies
2282015014824605/28/15 Surface anchored light chain bait antibody display system
2292015014832705/28/15 Substituted pyridine spleen tyrosine kinase (syk) inhibitors
2302015013998605/21/15 Ilt3 binding molecules and uses therefor
2312015014142805/21/15 Trka kinase inhibitors, compositions and methods thereof
2322015014144405/21/15 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
2332015012644305/07/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
2342015012649305/07/15 Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
2352015011939404/30/15 Insulin-like growth factor-1 receptor inhibitors
2362015011186604/23/15 Cyclic amine substituted heterocyclic cetp inhibitors
2372015011187704/23/15 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
2382015011191404/23/15 Spirolactam cgrp receptor antagonists
2392015010445304/16/15 Fdf03 antibodies and uses thereof
2402015010446504/16/15 Il-19 as a biomarker of tslp treatment
2412015010531704/16/15 Glucose-responsive insulin conjugates
2422015010535404/16/15 Heterocyclic aspartyl protease inhibitors
2432015009989104/09/15 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
2442015009971504/09/15 Formulations of acadesine
2452015009971904/09/15 Cathepsin cysteine protease inhibitors
2462015009972904/09/15 Inhibitors of the renal outer medullary potassium channel
2472015009977104/09/15 Pyridine cgrp receptor antagonists
2482015009339804/02/15 Methods and compositions for treating or preventing cancer
2492015008390603/26/15 Biomarkers for monitoring intervention therapies for diabetes



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###